Drug Discovery & Development | Industry Spotlights & Insight Articles
Immunostimulatory Oncolytic Viruses: Interview with Angelica Loskog, CEO, Lokon Pharma
Edited by Tom Cohen | 14 November 2023
Diving deep into Lokon Pharma's immunostimulatory oncolytic virus programme. Learn about their LOAd platform, transition to the clinic, and more.

https://www.youtube.com/watch?v=Uo1WsUGIEq0&ab_channel=OxfordGlobal
We had the privilege of sitting down with Angelica Loskog, Professor of Immunotherapy at Uppsala University in Sweden and the CEO of Lokon Pharma, a cutting-edge immunotherapy company making strides in the field. As a leader in the realm of oncolytic viruses and immunostimulatory gene therapy, Professor Loskog shared valuable insights into Lokon Pharma's groundbreaking work.
RELATED:
- Positive Phase I Data from Oncolytic Virotherapy Trial
- Oncolytic Virus Immunotherapy: A Revolutionary Approach in Immuno-Oncology
- William Coley, the Father of Cancer Immunotherapy and His Legacy
Speaker Biographies
Angelica has over 20 years immune oncology experience (Uppsala University and Baylor College of Medicine). She has a PhD in Medical Sciences from Uppsala University and is currently adjunct as a Professor of immunotherapy. She is an advisor to NEXTTOBE and is a board member of several of their portfolio companies.
Subscribe to our newsletter
Sign up for our monthly Newsletter to keep up with all things NextGen Biomed